Literature DB >> 17728322

Molecular mechanisms responsible for aberrant splicing of SERCA1 in myotonic dystrophy type 1.

Shin-Ichiro Hino1, Shinichi Kondo, Hiroshi Sekiya, Atsushi Saito, Soshi Kanemoto, Tomohiko Murakami, Kazuyasu Chihara, Yuri Aoki, Masayuki Nakamori, Masanori P Takahashi, Kazunori Imaizumi.   

Abstract

Myotonic dystrophy type 1 (DM1) is an autosomal dominant neuromuscular disorder associated with an expansion of CTG trinucleotide repeats in the 3'-untranslated region of the myotonic dystrophy protein kinase (DMPK) gene. The RNA gain-of-function hypothesis proposes that mutant DMPK mRNA alters the function and localization of alternative splicing regulators, which are critical for normal RNA processing. Previously, we found alternative splicing variants of sarcoplasmic/endoplasmic reticulum Ca(2+)-ATPase 1 (SERCA1), which excluded exon 22, in skeletal muscle of DM1 patients. In the present study, we analyzed the molecular mechanisms responsible for the splicing dysregulation of SERCA1. Five 'YGCU(U/G)Y' motifs that could potentially serve as Muscleblind-like 1, (MBNL1)-binding motifs, are included downstream from the SERCA1 exon 22. Exon trapping experiments showed that MBNL1 acts on the 'YGCU(U/G)Y' motif, and positively regulates exon 22 splicing. Of the five MBNL1 motifs in intron 22, the second and third sites were important for regulation of exon 22 splicing, but the other three binding sites were not required. Overexpression of the CUG repeat expansion of DMPK mRNA resulted in exclusion of exon 22 of SERCA1. These results suggest that sequestration of MBNL1 into the CUG repeat expansion of DMPK mRNA could cause the exclusion of SERCA1 exon 22, and the expression of this aberrant splicing form of SERCA1 could affect the regulation of Ca(2+) concentration of sarcoplasmic reticulum in DM patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17728322     DOI: 10.1093/hmg/ddm239

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  52 in total

1.  Muscle weakness in myotonic dystrophy associated with misregulated splicing and altered gating of Ca(V)1.1 calcium channel.

Authors:  Zhen Zhi Tang; Viktor Yarotskyy; Lan Wei; Krzysztof Sobczak; Masayuki Nakamori; Katy Eichinger; Richard T Moxley; Robert T Dirksen; Charles A Thornton
Journal:  Hum Mol Genet       Date:  2011-12-02       Impact factor: 6.150

2.  Design of a bioactive small molecule that targets the myotonic dystrophy type 1 RNA via an RNA motif-ligand database and chemical similarity searching.

Authors:  Raman Parkesh; Jessica L Childs-Disney; Masayuki Nakamori; Amit Kumar; Eric Wang; Thomas Wang; Jason Hoskins; Tuan Tran; David Housman; Charles A Thornton; Matthew D Disney
Journal:  J Am Chem Soc       Date:  2012-03-05       Impact factor: 15.419

3.  Reducing levels of toxic RNA with small molecules.

Authors:  Leslie A Coonrod; Masayuki Nakamori; Wenli Wang; Samuel Carrell; Cameron L Hilton; Micah J Bodner; Ruth B Siboni; Aaron G Docter; Michael M Haley; Charles A Thornton; J Andrew Berglund
Journal:  ACS Chem Biol       Date:  2013-09-27       Impact factor: 5.100

4.  Mechanistic determinants of MBNL activity.

Authors:  Łukasz J Sznajder; Michał Michalak; Katarzyna Taylor; Piotr Cywoniuk; Michał Kabza; Agnieszka Wojtkowiak-Szlachcic; Magdalena Matłoka; Patryk Konieczny; Krzysztof Sobczak
Journal:  Nucleic Acids Res       Date:  2016-10-12       Impact factor: 16.971

Review 5.  Myotonic dystrophy type 2 and modifier genes: an update on clinical and pathomolecular aspects.

Authors:  Giovanni Meola; Rosanna Cardani
Journal:  Neurol Sci       Date:  2017-01-11       Impact factor: 3.307

Review 6.  Antisense oligonucleotides: rising stars in eliminating RNA toxicity in myotonic dystrophy.

Authors:  Zhihua Gao; Thomas A Cooper
Journal:  Hum Gene Ther       Date:  2013-01-30       Impact factor: 5.695

7.  Transcriptome-wide regulation of pre-mRNA splicing and mRNA localization by muscleblind proteins.

Authors:  Eric T Wang; Neal A L Cody; Sonali Jog; Michela Biancolella; Thomas T Wang; Daniel J Treacy; Shujun Luo; Gary P Schroth; David E Housman; Sita Reddy; Eric Lécuyer; Christopher B Burge
Journal:  Cell       Date:  2012-08-17       Impact factor: 41.582

8.  Treatment of type 1 myotonic dystrophy by engineering site-specific RNA endonucleases that target (CUG)(n) repeats.

Authors:  Wenjing Zhang; Yang Wang; Shuyun Dong; Rajarshi Choudhury; Yongfeng Jin; Zefeng Wang
Journal:  Mol Ther       Date:  2013-10-23       Impact factor: 11.454

9.  MBNL and CELF proteins regulate alternative splicing of the skeletal muscle chloride channel CLCN1.

Authors:  Yoshihiro Kino; Chika Washizu; Yoko Oma; Hayato Onishi; Yuriko Nezu; Noboru Sasagawa; Nobuyuki Nukina; Shoichi Ishiura
Journal:  Nucleic Acids Res       Date:  2009-08-31       Impact factor: 16.971

10.  MBNL1 binds GC motifs embedded in pyrimidines to regulate alternative splicing.

Authors:  Emily S Goers; Jamie Purcell; Rodger B Voelker; Devika P Gates; J Andrew Berglund
Journal:  Nucleic Acids Res       Date:  2010-01-13       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.